WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 |

«B. PACKAGE LEAFLET Karvezide 150/12.5 mg tablets Irbesartan/hydrochlorothiazide PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR ...»

-- [ Page 1 ] --

B. PACKAGE LEAFLET

Karvezide 150/12.5 mg tablets

Irbesartan/hydrochlorothiazide

PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR

TABLETS

Your doctor has prescribed this medicine for you. Do not give it to anyone else. This leaflet contains a

summary of the information on your medicine. If you have questions or want more information, please

ask your doctor or pharmacist. Keep this leaflet while you are taking Karvezide tablets, as you may want to read it again.

COMPOSITION

The active substances in Karvezide tablets are irbesartan and hydrochlorothiazide. Each tablet of Karvezide 150/12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.

The tablets contain the following excipients: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica, pregelatinised maize starch, red and yellow ferric oxides (E172).

Karvezide tablets are supplied in blister packs of 28, 56 or 98.

TYPE OF MEDICINE

Karvezide is a combination of two active substances, irbesartan and hydrochlorothiazide.

Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists.

Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.

Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure.

The two active ingredients in Karvezide work together to lower blood pressure further than if either was given alone.

MARKETING AUTHORISATION HOLDER

BRISTOL-MYERS SQUIBB PHARMA EEIG

Swakeleys House, Milton Road Ickenham UB10 8 PU - United Kingdom

MANUFACTURER

SANOFI WINTHROP INDUSTRIE

1 rue de la Vierge F-33440 Ambarès - France WHEN SHOULD Karvezide BE USED?

Karvezide is used in the treatment of high blood pressure (hypertension), when a combination of two active substances is deemed appropriate. This is usually the case when treatment with one active substance alone did not provide adequate control of your blood pressure.

Your doctor measured your blood pressure and found it to be above the normal range for your age.

High blood pressure, if not treated, can damage blood vessels in several organs such as the heart, the kidneys, the brain and the eyes. In some instances, this may lead to heart attacks, heart or kidney failure, strokes, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus, measurement of the blood pressure is necessary to verify if it is in the normal range or not.

High blood pressure can be treated and controlled with medicines such as Karvezide. Your doctor may also have recommended that you adjust your lifestyle to help to lower your high blood pressure (losing weight, avoiding smoking, reducing alcohol consumption and restricting the amount of salt in the diet). Your doctor may also have encouraged the practice of regular, mild (not strenuous) exercise such as walking and swimming.

IMPORTANT INFORMATION BEFORE TAKING Karvezide:

When should Karvezide not be used?

Do not take Karvezide if:

you are or think you may be pregnant, • you are planning to become pregnant, • you are breast-feeding, • you have severe liver or kidney problems (ask your doctor if you have any doubt), • you have difficulty in producing urine, • you have a condition which is associated with persistently high calcium or low potassium levels •

–  –  –

If any of the above apply to you, inform your doctor or pharmacist first and ask for their advice.

Other appropriate precautions before use There are certain conditions that you may have, or have had, which require special care before or while taking Karvezide. Therefore, before taking this medicine, you should have told your doctor if

you suffer from:

excessive vomiting or diarrhoea, • kidney problems, including kidney transplantation, • heart problems, • liver problems, •

–  –  –

lupus erythematosus (also known as lupus or SLE).

• You should also tell your doctor if you are on a low-salt diet.

Signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat may indicate an excessive effect of hydrochlorothiazide (contained in Karvezide) for which you should consult your doctor.

If you are to undergo any surgery or receive anaesthetics, you should make sure the doctor knows that you are taking Karvezide tablets.

Hydrochlorothiazide contained in this medication could produce a positive result in an anti-doping test.

CAN YOU TAKE Karvezide WITH OTHER MEDICINES?

You should have informed your doctor of any medicines you are taking. These include medicines obtained without prescription.





Diuretic agents such as the hydrochlorothiazide contained in Karvezide may interact with other medicines. Preparations containing lithium should not be taken with Karvezide without close supervision by your doctor. Special precautionary measures (e.g. blood tests) may be appropriate if you take potassium supplements, potassium-containing salt substitutes or potassium sparing medicines, other diuretics (water tablets), some laxatives, medicines for the treatment of gout, therapeutic vitamin D supplements, medicines to control heart rhythm or for diabetes (oral agents or insulins). It is also important for your doctor to know if you are taking other medicines to reduce your blood pressure, steroids, medicines to treat cancer, pain killers or arthritis medicines.

CAN Karvezide BE USED DURING PREGNANCY OR BREAST-FEEDING?

Karvezide should not be used during pregnancy or if you are breast-feeding (see “When should Karvezide not be used”).

CAN YOU DRIVE OR OPERATE MACHINERY WHILE TAKING Karvezide?

Karvezide is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, you should consult your doctor before attempting such activities.

HOW SHOULD YOU TAKE Karvezide?

The tablets should be taken regularly as directed by your doctor.

Karvezide will usually be prescribed by your doctor when your previous treatment for high blood pressure did not provide appropriate blood pressure reduction. Your doctor will instruct you how to switch from the previous treatment to Karvezide.

The usual dose of Karvezide is one tablet a day. The maximal blood pressure lowering effect should be reached 6-8 weeks after beginning treatment. Should your blood pressure not be appropriately reduced with Karvezide, your doctor may prescribe an additional medicine.

Karvezide can be taken with or without food. The tablets should be swallowed with a drink of water.

You should try to take your daily dose at about the same time each day. It is important that you continue to take Karvezide until your doctor tells you otherwise.

Karvezide should not be given to children ( 18 years).

OVERDOSE If you accidentally take too many tablets, or a child swallows some, contact your doctor immediately.

MISSING A DOSE

If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for the missed dose.

ARE THERE SIDE EFFECTS WHEN TAKING Karvezide?

All medicines may cause some side effects.

Side effects with Karvezide are generally rare and of a temporary nature. They are generally mild and do not normally require treatment to be interrupted.

In clinical studies, symptoms or feelings most often reported by patients taking Karvezide or placebo (sugar tablets) included: headache, dizziness, fatigue, nausea/vomiting or abnormal urination. Of these, only fatigue was reported more often by patients taking Karvezide compared to patients taking placebo.

As for any combination of two active substances, side effects associated with each individual component cannot be excluded. In clinical studies with irbesartan alone, only minor injuries, most likely related to physical activity (like muscle and joint sprains), and on rare occasions flushing, were reported more often by patients taking irbesartan compared to patients taking placebo (sugar tablets). It was not clear if these were due to the medicine. The symptoms or feelings most often reported by patients taking irbesartan or placebo included: respiratory infections (like colds and flu), aches and pains (like headache and muscle aches), and dizziness. None of these was reported more often by patients taking irbesartan compared to patients taking placebo.

Rarely, patients taking similar medicines have developed localised swelling of the face, lips and/or tongue. This might also occur occasionally with irbesartan. If you think you are developing such a reaction or get short of breath stop taking Karvezide and seek immediate medical attention.

The other component of Karvezide (hydrochlorothiazide) has been associated rarely with other more serious side effects mainly affecting the blood, the skin or the kidneys. While this was not observed with Karvezide, occurrence of such side effects cannot be excluded.

If you notice abnormal symptoms or feelings while taking Karvezide, you should inform your doctor or pharmacist and ask for their advice.

HOW SHOULD YOU STORE YOUR Karvezide TABLETS?

Keep all medicines out of the reach of children.

Do not store above 30°C.

Store in the original package.

You will see an expiry date on the carton and on the blister. Do not use the tablets after this date. Do not remove the tablets from the blister pack until you are ready to take the medicine.

DATE OF LAST REVISION OF THIS LEAFLET

OTHER INFORMATION

If you would like more information on your disease or treatment, you should ask your doctor or pharmacist.

Further information For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.

–  –  –

PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TO TAKE YOUR

TABLETS Your doctor has prescribed this medicine for you. Do not give it to anyone else. This leaflet contains a summary of the information on your medicine. If you have questions or want more information, please ask your doctor or pharmacist. Keep this leaflet while you are taking Karvezide tablets, as you may want to read it again.

COMPOSITION

The active substances in Karvezide tablets are irbesartan and hydrochlorothiazide. Each tablet of Karvezide 300/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.

The tablets contain the following excipients: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica, pregelatinised maize starch, red and yellow ferric oxides (E172).

Karvezide tablets are supplied in blister packs of 28, 56 or 98.

TYPE OF MEDICINE

Karvezide is a combination of two active substances, irbesartan and hydrochlorothiazide.

Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists.

Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.

Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure.

The two active ingredients in Karvezide work together to lower blood pressure further than if either was given alone.

MARKETING AUTHORISATION HOLDER

BRISTOL-MYERS SQUIBB PHARMA EEIG

Swakeleys House, Milton Road Ickenham UB10 8 PU - United Kingdom

MANUFACTURER

SANOFI WINTHROP INDUSTRIE

1 rue de la Vierge F-33440 Ambarès - France WHEN SHOULD Karvezide BE USED?

Karvezide is used in the treatment of high blood pressure (hypertension), when a combination of two active substances is deemed appropriate. This is usually the case when treatment with one active substance alone did not provide adequate control of your blood pressure.

Your doctor measured your blood pressure and found it to be above the normal range for your age.

High blood pressure, if not treated, can damage blood vessels in several organs such as the heart, the kidneys, the brain and the eyes. In some instances, this may lead to heart attacks, heart or kidney failure, strokes, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus, measurement of the blood pressure is necessary to verify if it is in the normal range or not.

High blood pressure can be treated and controlled with medicines such as Karvezide. Your doctor may also have recommended that you adjust your lifestyle to help to lower your high blood pressure (losing weight, avoiding smoking, reducing alcohol consumption and restricting the amount of salt in the diet). Your doctor may also have encouraged the practice of regular, mild (not strenuous) exercise such as walking and swimming.

IMPORTANT INFORMATION BEFORE TAKING Karvezide:

When should Karvezide not be used?

Do not take Karvezide if:



Pages:   || 2 |


Similar works:

«  Robotic Barn Design Part 2: Principles of Robotic Barn Design on Cow Flow, Cow Comfort and Cow Health Jack Rodenburg DairyLogix 173 Falcon Drive Woodstock, ON N4T 1W5 Tel: (519) 290-7194 Fax: (519) 290-7676 E-mail: jack@dairylogix.com The Robot Room Many popular barn layouts feature robot rooms that include more than one robot. While this is convenient for cleaning and servicing it has several disadvantages. Air and vacuum leaks and straining bearings and joints can often be heard before...»

«.Public R&D Investments and Private Sector Patenting: ∗ Evidence from NIH Funding Rules Pierre Azoulay†, Joshua Graff-Zivin‡, Danielle Li§, and Bhaven Sampat PRELIMINARY & INCOMPLETE Comments are very welcome, but please do not cite or distribute without permission This version: May 8, 2014 Abstract This paper measures the impact of public R&D investments on innovation by private sector firms. We quantify the returns to grant spending at the National Institutes of Health (NIH) in...»

«Manual Osteopathic Management of the T.M.J. Disorders I Manual Osteopathic Management of the Temporomandibular Joint Disorders Joseph A.A. Arrindell Jr. PT, CMP, DO (cand) National University of Medical Sciences Author Note The Temporomandibular joint (TMJ) is the second most common source of facial pain, second to toothache. Ten million people in the United States are affected by TMJ and roughly 25% of the population can have symptoms at some point in their lives. The morbidity of the disorder...»

«T-9.1 SWANA TECHNICAL POLICY PROVIDING FINANCIAL ASSURANCE FOR MUNICIPAL SOLID WASTE MANAGEMENT DISPOSAL FACILITIES I. BACKGROUND The management of municipal solid waste utilizes a number of intermediate steps (collection, curbside recycling, transfer, materials recovery, combustion, etc.) before some portion of the solid waste is presented for final disposal in a landfill. In addition, several of the processes result in residue that must also be disposed of in a landfill. Finally, there are...»

«My Lupus What I need to know A Young Person's Guide Published by LUPUS UK (Registered Charity nos. 1061510, SC0396820) St James House, Eastern Road, Romford, Essex RM1 3NH © LUPUS UK 2009 All rights reserved. No part of this book may be reproduced in any form without written permission from LUPUS UK. Readers are strongly advised to consult with their medical team if requiring further advice on matters reported in this publication. My Lupus: What I Need to Know Index Overview • o Introduction...»

«Epidemiology of Streptococcus pneumoniae: Molecular characterisation, antibiotic sensitivity and serotyping of Hungarian isolates Dobay Orsolya Semmelweis University, Institute of Medical Microbiology Doctoral (Ph.D.) thesis Semmelweis University, School of Ph.D. Studies Pathology Interdisciplinar Doctoral School Programme 8/3: Studies on the effects of microorganisms and their products at molecular, cellular and organism levels Programme leader: Prof. Ferenc Rozgonyi, MD, PhD, DSc Project...»

«A Framework for Accredited Scientific Practice (ASP) in Healthcare Science: A Strategic Approach to Continuing Personal and Professional Development Prepared for: Professor Sue Hill, Chief Scientific Officer Prepared by: Professor Shelley Heard, Ian Clarke, Susan Kennedy February 2015 Contents 1. Foreword 2. Background and context 3. Rationale for Accredited Scientific Practice (ASP) 4. The Framework 5. Purpose and principles underlying this framework 6. Governance arrangements 7. Education and...»

«Ronald M. Green, PhD Ethics Institute Director and Professor of Religion, Dartmouth College and George A. Little, MD Neonatologist and Professor of Pediatrics, Dartmouth-Hitchcock Medical Center The Ethics Institute and the Department of Pediatrics Dartmouth College, Hanover, New Hampshire In Our Midst is available from: Fanlight Productions 4196 Washington Street Boston, MA 02131 (800) 937-4113 Fax (617) 469-3379 Email: info@fanlight.com Website: www.fanlight.com Copyright 2003, The Trustees...»

«Nathan J. Hillson Joint BioEnergy Institute 5885 Hollis Street, Fourth Floor Emeryville, CA 94608 Phone: (510) 486-6754 E-mail: njhillson@lbl.gov EDUCATION Stanford University School of Medicine, Stanford CA Postdoctoral Fellowship, Microbiology, 2009 Harvard Medical School, Boston MA Ph.D., Biophysics, 2004 Rice University, Houston TX B.A., Physics; Computational and Applied Mathematics, cum laude, 1999 Selected Course Work: Macromolecular X-ray Crystallography; Chemical Biology; Simulation of...»

«State of California—Health and Human Services Agency Department of Health Care Services TOBY DOUGLAS EDMUND G. BROWN JR. DIRECTOR GOVERNOR November 16, 2012 TO: ALL COUNTY WELFARE DIRECTORS ALL COUNTY WELFARE ADMINISTRATIVE OFFICERS ALL COUNTY MEDI-CAL PROGRAM SPECIALISTS/LIAISIONS ALL COUNTY HEALTH EXECUTIVES ALL COUNTY MENTAL HEALTH DIRECTORS ALL COUNTY MEDS LIAISONS SUBJECT: Targeted Low-Income Children’s Program Letter No.: 12-33 The purpose of this All County Welfare Directors Letter...»

«DARTMOUTH COLLEGE HANOVER, NEW HAMPSHIRE SEPTEMBER, 2005 Special Assistance Needs and Disability Emergency Building Evacuation Plan The content of this document is for informational purposes only. It is not intended for medical or legal advice. This brochure provides a general guideline of evacuation procedures for people with special needs and/or disabilities in case of fire and other building emergencies. Dartmouth students and employees who may require special assistance in the event of an...»

«PUBLISHED BY World's largest Science, Technology & Medicine Open Access book publisher 96,000+ 2750+ 89+ MILLION INTERNATIONAL AUTHORS AND EDITORS OPEN ACCESS BOOKS DOWNLOADS AUTHORS AMONG 12.2% BOOKS TOP 1% AUTHORS AND EDITORS DELIVERED TO MOST CITED SCIENTIST FROM TOP 500 UNIVERSITIES 151 COUNTRIES Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI) Chapter from the book Ophthalmology Current Clinical and Research Updates Downloaded from:...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.